Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia

A. K. Tiwari, C. C. Zai, O. Likhodi, A. N. Voineskos, H. Y. Meltzer, J. A. Lieberman, S. G. Potkin, G. Remington, D. J. Müller, J. L. Kennedy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Tardive dyskinesia (TD) is a severe, debilitating movement disorder observed in 25-30% of the patients treated with typical antipsychotics. Cannabinoid receptor 1 (CNR1) activators tend to inhibit movement, an effect prevented by rimonabant and other selective CNR1 antagonists. Furthermore, CNR1 receptor is downregulated in Huntington's disease and upregulated in Parkinson's disease. Twenty tagSNPs spanning the CNR1 gene were analyzed in schizophrenia patients of European ancestry (n=191; 74 with TD). Significant genotypic (P=0.012) and allelic (P=0.012) association was observed with rs806374 (T>C). Carriers of the CC genotype were more likely to be TD positive (CC vs TT+TC, odds ratio=3.4 (1.5-7.8), P=0.003) and had more severe TD (CC vs TT+TC; 9.52±9.2 vs 5.62±6.9, P=0.046). These results indicate a possible role of CNR1 in the development of TD in our patient population. However, these observations are marginal after correcting for multiple testing and need to be replicated in a larger patient population.

Original languageEnglish (US)
Pages (from-to)260-266
Number of pages7
JournalPharmacogenomics Journal
Issue number3
StatePublished - Jun 2012


  • CNR1
  • association
  • genetics
  • movement
  • schizophrenia
  • tardive dyskinesia

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia'. Together they form a unique fingerprint.

Cite this